Co-Pay & Reimbursement Assistance for NUWIQ®️ Treatment

Octapharma Co-Pay Assistance Program

The Octapharma Co-Pay Assistance Program available through Factor My Way^® can provide eligible patients with significant savings on some of the costs associated with their NUWIQ treatment. If you’re currently using NUWIQ, or if you’re about to begin therapy, our Co-Pay Assistance Program can offer savings up to

$12,000

per year on the out-of-pocket costs associated with your therapy.

How Do I Enroll?

It’s simple. Visit Factor My Way to get started, or call the Factor My Way Support Center at 1-855-498-4260 and let them know you’d like to enroll in the Co-Pay Assistance Program.

Help When You Need It

The Factor My Way Support Center offers expert advice about insurance matters impacting coverage of your treatment costs – individual claims processing reviews, assistance in appeals, insurance investigations into product coverage, and gaining approvals for prior authorizations for factor treatments. Support Center Representatives can also answer questions about the Factor My Way financial assistance programs and eligibility. Representatives are available Monday – Friday from 8:30 am – 5:00 pm, EST. Call 1-855-498-4260.

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>5%) in clinical trials were upper respiratory tract infection, headache, fever, cough, lower respiratory tract infection, rhinitis, chills, abdominal pain, arthralgia, anemia, and pharyngitis.

Please See NUWIQ full Prescribing Information. Instructions For Use